Capricor Therapeutics
8840 Wilshire Blvd
2nd Floor
Beverly Hills
California
90211
United States
142 articles with Capricor Therapeutics
-
Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
7/27/2021
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, today announced the appointment of Karimah Es Sabar to its Board of Directors, effective immediately.
-
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
6/17/2021
Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Company’s ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference.
-
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
6/10/2021
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that the company will participate in 1x1 meetings with investors and potential partners at BIO Digital 2021 being held June 10-11 and June 14-18, 2021.
-
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
4/29/2021
Capricor Therapeutics, a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced that it has signed an exclusive, worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics as part of the Company’s exosome technology portfolio.
-
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
1/19/2021
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement-
-
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
1/12/2021
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity for potential late-stage clinical trials and commercialization— —Process development to take place in Lonza’s Houston (TX) center of excellence—
-
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial
12/29/2020
Capricor Therape u tics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the independent Data and Safety Monitoring Board (DSMB) has completed its safety review for Capricor’s Phase II IN S PIR E study. The DSMB recommend
-
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
11/24/2020
Capricor Therapeutics, Inc. announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002
-
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
11/9/2020
Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy
-
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12Company to Host Conference Call and Webcast, November 12, 2020, at 4:30 p.m. ET
11/5/2020
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today, that it will release its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 12, 2020. Company management will host a conference call and webcast to discuss its financial
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
-
Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET
7/30/2020
Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that it will release its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Company management will host a conference call and webcast to discuss its financial resul
-
Capricor to Participate in BIO Digital International Convention
6/4/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that it will be participating in the upcoming BIO Digital International Convention. Details: Event: BIO Digital 2020 Date: J
-
Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
5/26/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today that Capricor’s CEO, Linda Marbán, Ph.D, will participate on the panel “ Cell therapy for ARDS - When Remdesivir is not enough " hosted by Maxim Group and M-Vest on Wednesday, May 27 beginning at 10:00 a.m. Eastern time (7:00 a
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
-
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/14/2020
Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)
-
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
5/13/2020
-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that Correlates Stabilization in Cardiac Function with a Reduction in a Biomarker of Cell Damage- -Company Planning to Meet with FDA to Discuss Pathway to Approval- -To Host Conference Call and Webcast Today at 8AM ET- LOS ANGELES, May 13, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a
-
New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients
4/29/2020
Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compa
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
-
Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy
4/13/2020
Capricor Therapeutics today announced that it will host a Key Opinion Leader (KOL) call on the cardiac complications of DMD on Wednesday, April 15, 2020 at 1:30 pm Easter